American Board of Surgery Qualifying Exam (ABS QE) Practice Test

Dacarbazine is commonly used in the treatment of metastatic melanoma due to its effectiveness as a chemotherapy agent specifically targeting this type of cancer. It is considered a standard treatment option among various regimens aimed at managing metastatic melanoma. Dacarbazine works as an alkylating agent that causes damage to DNA, inhibiting the growth of cancer cells and leading to their death. Metastatic melanoma has historically been challenging to treat, and while immunotherapy and targeted therapies have become prevalent, Dacarbazine remains a recognized option within combination therapies and specific treatment plans. It has also been part of clinical trials and guidelines for the management of advanced melanoma. Other agents listed, such as Cisplatin, Paclitaxel, and Bleomycin, have roles in treating different types of cancer but are not standard options for metastatic melanoma. Each of these alternatives is more commonly associated with other malignancies, and they do not have the same efficacy profile against melanoma as Dacarbazine does. Therefore, their use in this context is limited compared to Dacarbazine, which has a well-established role in managing this particular disease.